Driving Excellence in Diagnostics
GBC has been honored with the 2025 Taiwan Excellence Award for its CellBio™ FX10 system, a milestone in circulating tumor cell (CTC) detection. This prestigious award celebrates products that exemplify “innovation, design, quality, and marketability,” and underscores that CellBio™ FX10 sets the bar in diagnostic instrumentation.
Technical Innovation with Patented iFiltration™
Powered by GBC’s proprietary iFiltration™ technology, CellBio™ FX10 efficiently captures circulating tumor cells directly from minimal blood samples, achieving over 90% capture rate. This non-invasive, high-precision method supports early cancer detection and dynamic disease monitoring.
Impacting Cancer Research and Clinical Practice
With its automation and sensitivity, CellBio™ FX10 enables timely detection of tumor cells, aiding clinicians in treatment planning, patient monitoring, and early intervention—critical in precision oncology.
Comprehensive Recognition of GBC’s R&D Strength
Winning the Taiwan Excellence Award affirms GBC’s leadership in in vitro diagnostics, precision instrumentation, and oncology monitoring, reflecting our ongoing dedication to healthcare innovation.
